Positive Outlook for Jasper Therapeutics: Promising Clinical Developments and Strategic Updates Support Buy Rating

William Blair analyst Matt Phipps has maintained their bullish stance on JSPR stock, giving a Buy rating yesterday.

Matt Phipps has given his Buy rating due to a combination of factors including Jasper Therapeutics’ promising developments in their clinical studies. The upcoming European Academy of Allergy and Clinical Immunology Congress will feature additional data from the SPOTLIGHT study on briquilimab for chronic inducible urticaria, showcasing its potential efficacy at higher doses. This follows earlier positive results from a lower dose, indicating a strong therapeutic profile.
Furthermore, Jasper’s BEACON study on chronic spontaneous urticaria has shown encouraging trends, with further updates expected in the third quarter of 2025. These updates will include data from new patient cohorts, which could further validate briquilimab’s effectiveness. The anticipation of these results and the strategic timing of corporate updates suggest a positive outlook for Jasper’s clinical pipeline, supporting the Buy rating.

Phipps covers the Healthcare sector, focusing on stocks such as Incyte, Bristol-Myers Squibb, and Genmab. According to TipRanks, Phipps has an average return of -11.0% and a 32.37% success rate on recommended stocks.